patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_785084 | REC_0005501 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 12.7 | 70 | female | 2 | 23 | 4.8 | 5 | alectinib 600 mg BID | 8.5 | false | MSS | 2026-03-15T05:35:58.206260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109902 | REC_0005502 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.1 | 72 | female | 1 | 14 | 4.9 | 5 | sotorasib 960 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:58.206493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774311 | REC_0005503 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.5 | 68 | female | 1 | 67 | 4.6 | 7 | pembrolizumab 200 mg q3w | 8.7 | false | MSS | 2026-03-15T05:35:58.206723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118532 | REC_0005504 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 21.3 | 64 | female | 1 | 16 | 4.8 | 1 | alectinib 600 mg BID | 23.2 | true | MSI-H | 2026-03-15T05:35:58.206956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175810 | REC_0005505 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.1 | 60 | female | 0 | 6 | 6 | 7 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:58.207190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760306 | REC_0005506 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 15.9 | 69 | female | 0 | 1 | 7.1 | 5 | osimertinib 80 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:58.207420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409829 | REC_0005507 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.4 | 72 | female | 1 | 11 | 3.2 | 1 | entrectinib 600 mg daily | 21.5 | false | MSS | 2026-03-15T05:35:58.207653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381814 | REC_0005508 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 36 | 7.5 | 56 | female | 1 | 59 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.4 | true | MSS | 2026-03-15T05:35:58.207887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475484 | REC_0005509 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.7 | 86 | female | 2 | 13 | 5.5 | 2 | osimertinib 80 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:58.208238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102391 | REC_0005510 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 12.6 | 66 | female | 0 | 6 | 5.5 | 1 | osimertinib 80 mg daily | 18.2 | true | MSI-H | 2026-03-15T05:35:58.208483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613059 | REC_0005511 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 14.3 | 87 | female | 0 | 18 | 6 | 1 | osimertinib 80 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:35:58.208962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761542 | REC_0005512 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.5 | 76 | female | 3 | 51 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:58.209204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274814 | REC_0005513 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 15.2 | 71 | female | 2 | 13 | 6.2 | 1 | sotorasib 960 mg daily | 11 | true | MSI-H | 2026-03-15T05:35:58.209536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609905 | REC_0005514 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.6 | 79 | female | 2 | 4 | 4.2 | 6 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:58.209772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331401 | REC_0005515 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 9.9 | 77 | female | 1 | 24 | 6 | 2 | entrectinib 600 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:58.210003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551700 | REC_0005516 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 36 | 13.9 | 63 | male | 0 | 10 | 7.1 | 7 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.210240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122738 | REC_0005517 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 14.7 | 68 | female | 0 | 11 | 4.9 | 1 | sotorasib 960 mg daily | 24.9 | true | MSI-H | 2026-03-15T05:35:58.210472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582574 | REC_0005518 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 3.5 | 58 | male | 0 | 51 | 6.4 | 5 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:35:58.210704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524690 | REC_0005519 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 8.2 | 59 | male | 0 | 24 | 4.5 | 2 | pembrolizumab 200 mg q3w | 11.6 | false | MSS | 2026-03-15T05:35:58.210939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245512 | REC_0005520 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.8 | 70 | female | 1 | 68 | 3.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:58.211169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824755 | REC_0005521 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 8 | 83 | female | 2 | 53 | 4.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.6 | true | MSS | 2026-03-15T05:35:58.211398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498146 | REC_0005522 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 16.4 | 86 | female | 2 | 4 | 6.5 | 5 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:58.211632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785600 | REC_0005523 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 14.7 | 64 | male | 0 | 22 | 7.9 | 2 | alectinib 600 mg BID | 12.1 | false | MSI-H | 2026-03-15T05:35:58.211868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590758 | REC_0005524 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.7 | 46 | male | 0 | 50 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.7 | true | MSS | 2026-03-15T05:35:58.212176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310631 | REC_0005525 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 8.4 | 66 | female | 1 | 20 | 3.6 | 1 | osimertinib 80 mg daily | 17.7 | false | MSS | 2026-03-15T05:35:58.212414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109481 | REC_0005526 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 9.1 | 67 | male | 1 | 11 | 3.5 | 4 | entrectinib 600 mg daily | 6 | false | MSS | 2026-03-15T05:35:58.212800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696773 | REC_0005527 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.7 | 73 | female | 2 | 17 | 5.1 | 7 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:58.213041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224097 | REC_0005528 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10.4 | 73 | female | 2 | 16 | 5.7 | 2 | osimertinib 80 mg daily | 21.5 | true | MSI-H | 2026-03-15T05:35:58.213338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589370 | REC_0005529 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.3 | 69 | male | 1 | 33 | 2.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.4 | false | MSS | 2026-03-15T05:35:58.213576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757889 | REC_0005530 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 8.2 | 65 | male | 1 | 9 | 7.7 | 2 | osimertinib 80 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:58.213809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551537 | REC_0005531 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 35 | 12 | 63 | male | 1 | 22 | 7.3 | 1 | sotorasib 960 mg daily | 21.4 | false | MSS | 2026-03-15T05:35:58.214087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712384 | REC_0005532 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.3 | 65 | male | 0 | 17 | 6.1 | 3 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:58.214323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529659 | REC_0005533 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.7 | 62 | female | 1 | 35 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 13 | true | MSS | 2026-03-15T05:35:58.214557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923883 | REC_0005534 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 6.4 | 75 | female | 2 | 66 | 4.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 6 | true | MSS | 2026-03-15T05:35:58.214785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883253 | REC_0005535 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 33 | 3.8 | 70 | male | 2 | 34 | 4.5 | 0 | pembrolizumab 200 mg q3w | 29.3 | false | MSS | 2026-03-15T05:35:58.215063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569242 | REC_0005536 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12.2 | 57 | female | 0 | 23 | 3.4 | 2 | sotorasib 960 mg daily | 19.4 | true | MSS | 2026-03-15T05:35:58.215302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366892 | REC_0005537 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.1 | 51 | female | 0 | 7 | 4.7 | 7 | osimertinib 80 mg daily | 4.4 | true | MSI-H | 2026-03-15T05:35:58.215537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778681 | REC_0005538 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.3 | 71 | male | 3 | 17 | 6.4 | 1 | entrectinib 600 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:35:58.215773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728849 | REC_0005539 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.8 | 66 | female | 1 | 12 | 6.4 | 4 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:58.216215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461655 | REC_0005540 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.2 | 63 | male | 1 | 9 | 4.7 | 3 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:58.216473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566287 | REC_0005541 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 8.4 | 73 | male | 0 | 16 | 6 | 1 | pembrolizumab 200 mg q3w | 15.1 | true | MSS | 2026-03-15T05:35:58.216711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591146 | REC_0005542 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 17.1 | 76 | female | 1 | 21 | 6.9 | 4 | alectinib 600 mg BID | 14.7 | true | MSI-H | 2026-03-15T05:35:58.216943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271899 | REC_0005543 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17.7 | 46 | male | 0 | 18 | 6.9 | 6 | alectinib 600 mg BID | 7.9 | true | MSS | 2026-03-15T05:35:58.217182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616847 | REC_0005544 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.7 | 54 | female | 0 | 10 | 3.9 | 6 | osimertinib 80 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:58.217418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749546 | REC_0005545 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 10.1 | 58 | female | 1 | 30 | 4.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:35:58.217656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996376 | REC_0005546 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.6 | 68 | female | 1 | 42 | 5.8 | 4 | pembrolizumab 200 mg q3w | 6.2 | false | MSS | 2026-03-15T05:35:58.217887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402220 | REC_0005547 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 15.2 | 57 | male | 0 | 10 | 6.2 | 1 | sotorasib 960 mg daily | 25.1 | false | MSI-H | 2026-03-15T05:35:58.218125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141647 | REC_0005548 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 7.2 | 54 | male | 0 | 16 | 5.3 | 1 | alectinib 600 mg BID | 23.7 | true | MSS | 2026-03-15T05:35:58.218355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771895 | REC_0005549 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 32 | 6.5 | 78 | female | 2 | 7 | 5.6 | 0 | alectinib 600 mg BID | 17.1 | false | MSS | 2026-03-15T05:35:58.218582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809651 | REC_0005550 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 10.2 | 61 | male | 1 | 54 | 4.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.6 | true | MSI-H | 2026-03-15T05:35:58.218818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697716 | REC_0005551 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 17.2 | 74 | female | 3 | 12 | 7.9 | 7 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:58.219051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597485 | REC_0005552 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12 | 77 | male | 2 | 11 | 5 | 4 | sotorasib 960 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:58.219337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669909 | REC_0005553 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 1.9 | 65 | male | 1 | 49 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 30.8 | true | MSS | 2026-03-15T05:35:58.219570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185132 | REC_0005554 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 8.6 | 74 | male | 2 | 0 | 4.7 | 0 | osimertinib 80 mg daily | 53.9 | true | MSS | 2026-03-15T05:35:58.219803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888469 | REC_0005555 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 8.6 | 72 | female | 2 | 13 | 6.5 | 1 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:58.220031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941914 | REC_0005556 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 6.8 | 73 | female | 2 | 17 | 3.4 | 5 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:35:58.220303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459978 | REC_0005557 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 10.8 | 57 | female | 0 | 17 | 6.6 | 1 | alectinib 600 mg BID | 20.1 | false | MSI-H | 2026-03-15T05:35:58.220542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373114 | REC_0005558 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.2 | 59 | male | 0 | 21 | 4.9 | 9 | alectinib 600 mg BID | 13.1 | false | MSI-H | 2026-03-15T05:35:58.220777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117708 | REC_0005559 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 6.9 | 61 | female | 0 | 45 | 4.8 | 0 | pembrolizumab 200 mg q3w | 18.2 | false | MSS | 2026-03-15T05:35:58.221012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495488 | REC_0005560 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 19.7 | 73 | female | 1 | 10 | 4.8 | 5 | alectinib 600 mg BID | 8 | false | MSI-H | 2026-03-15T05:35:58.221245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196567 | REC_0005561 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.5 | 64 | male | 1 | 8 | 5.6 | 4 | alectinib 600 mg BID | 12.3 | true | MSI-H | 2026-03-15T05:35:58.221481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526367 | REC_0005562 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.1 | 88 | male | 2 | 61 | 4.3 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.5 | false | MSS | 2026-03-15T05:35:58.221711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186908 | REC_0005563 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 6.3 | 73 | female | 1 | 9 | 4.9 | 1 | sotorasib 960 mg daily | 15 | true | MSS | 2026-03-15T05:35:58.221943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488392 | REC_0005564 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 13.7 | 78 | female | 0 | 13 | 4.9 | 1 | osimertinib 80 mg daily | 25.6 | false | MSS | 2026-03-15T05:35:58.222173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865426 | REC_0005565 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 8.4 | 63 | male | 1 | 13 | 3.9 | 2 | alectinib 600 mg BID | 15.9 | false | MSS | 2026-03-15T05:35:58.222453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653259 | REC_0005566 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 16.1 | 70 | female | 1 | 11 | 4.9 | 2 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.222693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330895 | REC_0005567 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.5 | 61 | female | 1 | 22 | 6 | 1 | pembrolizumab 200 mg q3w | 20.1 | true | MSS | 2026-03-15T05:35:58.222927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549558 | REC_0005568 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.3 | 69 | female | 0 | 51 | 5.7 | 7 | pembrolizumab 200 mg q3w | 5.6 | true | MSS | 2026-03-15T05:35:58.223155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677999 | REC_0005569 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 27 | 6 | 75 | female | 3 | 13 | 6 | 0 | pembrolizumab 200 mg q3w | 34.9 | false | MSS | 2026-03-15T05:35:58.223383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476410 | REC_0005570 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 7.4 | 67 | male | 0 | 9 | 7.2 | 6 | osimertinib 80 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:58.223615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590314 | REC_0005571 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 16.6 | 66 | female | 0 | 9 | 4.8 | 7 | entrectinib 600 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:58.223852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274022 | REC_0005572 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.5 | 54 | female | 0 | 34 | 6.9 | 5 | pembrolizumab 200 mg q3w | 4.5 | false | MSS | 2026-03-15T05:35:58.224108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317231 | REC_0005573 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 3.9 | 63 | male | 1 | 13 | 6.5 | 7 | osimertinib 80 mg daily | 16.8 | true | MSS | 2026-03-15T05:35:58.224345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787067 | REC_0005574 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.8 | 75 | male | 2 | 24 | 5.2 | 9 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:58.224582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219511 | REC_0005575 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 17.9 | 84 | female | 2 | 12 | 7.6 | 0 | entrectinib 600 mg daily | 64.4 | false | MSS | 2026-03-15T05:35:58.224816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653443 | REC_0005576 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 10.2 | 72 | female | 1 | 19 | 7.8 | 2 | osimertinib 80 mg daily | 17.8 | true | MSS | 2026-03-15T05:35:58.225051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839475 | REC_0005577 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.2 | 65 | female | 0 | 36 | 4.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 18.7 | false | MSS | 2026-03-15T05:35:58.225282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974698 | REC_0005578 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.8 | 72 | female | 1 | 18 | 5.1 | 6 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.225587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504809 | REC_0005579 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.8 | 85 | female | 3 | 57 | 6.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 10 | true | MSS | 2026-03-15T05:35:58.225823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922993 | REC_0005580 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 10.5 | 73 | female | 2 | 13 | 3.7 | 3 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.226080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192602 | REC_0005581 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.3 | 90 | male | 0 | 18 | 6.4 | 8 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:58.226353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464514 | REC_0005582 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 12 | 1.8 | 58 | male | 0 | 60 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 4.6 | false | MSS | 2026-03-15T05:35:58.226586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793385 | REC_0005583 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 16.8 | 74 | female | 2 | 7 | 7.2 | 7 | osimertinib 80 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:35:58.226824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117288 | REC_0005584 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 8.1 | 62 | male | 1 | 48 | 6.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.227056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734538 | REC_0005585 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 3.7 | 59 | female | 0 | 48 | 3.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 30.2 | true | MSS | 2026-03-15T05:35:58.227289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836772 | REC_0005586 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.7 | 71 | male | 2 | 53 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:35:58.227522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754974 | REC_0005587 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 5.8 | 74 | male | 1 | 13 | 5.6 | 3 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:58.227756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761274 | REC_0005588 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 14 | 60 | male | 1 | 12 | 3.6 | 4 | entrectinib 600 mg daily | 14 | false | MSI-H | 2026-03-15T05:35:58.227989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846425 | REC_0005589 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 15.8 | 66 | female | 1 | 10 | 4.8 | 1 | pembrolizumab 200 mg q3w | 21.1 | true | MSS | 2026-03-15T05:35:58.228263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342674 | REC_0005590 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.7 | 60 | male | 1 | 46 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.5 | true | MSS | 2026-03-15T05:35:58.228510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281609 | REC_0005591 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 15.1 | 69 | female | 0 | 23 | 5.3 | 7 | entrectinib 600 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:58.228792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283990 | REC_0005592 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.6 | 77 | female | 2 | 10 | 5.6 | 6 | osimertinib 80 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:58.229033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387758 | REC_0005593 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 15.9 | 63 | female | 0 | 20 | 5.3 | 7 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:58.229268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310558 | REC_0005594 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 6.7 | 58 | female | 0 | 13 | 7 | 2 | alectinib 600 mg BID | 24.3 | false | MSS | 2026-03-15T05:35:58.229501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810531 | REC_0005595 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.3 | 65 | female | 1 | 13 | 4.9 | 6 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:58.229736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719363 | REC_0005596 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 7.5 | 48 | female | 0 | 10 | 4 | 1 | sotorasib 960 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:58.229967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127301 | REC_0005597 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 29 | 9.2 | 64 | female | 1 | 15 | 6.5 | 0 | pembrolizumab 200 mg q3w | 23.7 | false | MSS | 2026-03-15T05:35:58.230199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923950 | REC_0005598 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 9.5 | 57 | male | 1 | 19 | 5.5 | 0 | entrectinib 600 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:58.230430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790751 | REC_0005599 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 39 | 9.9 | 54 | male | 0 | 8 | 3.7 | 8 | entrectinib 600 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:58.230663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427740 | REC_0005600 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 14.2 | 53 | female | 0 | 19 | 5.3 | 2 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:35:58.230900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.